11 publicly disclosed transactions where Bloom Burton & Co. played an advisory, financing or investing role, most recent first.
Sep 15, 2026
Apotex Health Corp.
Underwriter (syndicate member) · Pharmaceuticals
Seller Affiliate of SK Capital Partners; API Investment LP (Sherfam); Allan Oberman
Upsized bought-deal secondary offering of 25,000,000 Apotex Health shares at $34.00 by selling shareholders, for gross proceeds of $850 million; Apotex received no proceeds. RBC Capital Markets, TD Securities and Scotiabank were joint lead bookrunners, and Bloom Burton Securities was one of the syndicate underwriters. The date shown as announced is the prospectus supplement date.
Sep 11, 2026
BetterLife Pharma Inc.
Lead agent · Biotechnology
Vancouver-based BetterLife Pharma (CSE: BETR) closed a US$100 million public offering of common shares and pre-funded warrants on a commercially reasonable efforts agency basis; the date shown as announced is the agency agreement date. Haywood Securities was co-agent.
Jun 30, 2026
Andone Pharmaceuticals Inc.
Exclusive financial advisor to Andone · Pharmaceuticals / Medical Devices / Veterinary
Buyer SteriMax Inc.
SteriMax acquired Andone, an Oakville, Ontario pharmaceutical and medical device company,, expanding into medical device and veterinary markets. Bourne Partners advised SteriMax.
Jun 24, 2026
Helus Pharma
Lead manager (with Lucid Capital Markets) · Biotechnology
US$50 million underwritten offering of common shares at US$4.85 by Nasdaq- and Cboe Canada-listed Helus Pharma (New York and Toronto). Cantor and Barclays were joint bookrunners.
Apr 2, 2024
Searchlight Pharma Inc.
Financial advisor to Searchlight · Pharmaceuticals
Buyer Apotex Inc.
Apotex agreed to acquire private specialty branded pharmaceutical company Searchlight Pharma to expand beyond generics and biosimilars.
Apr 2, 2024
Appili Therapeutics Inc.
Financial advisor to the Appili board · Biotechnology
Buyer Aditxt, Inc.
Aditxt agreed to acquire Appili for cash and Aditxt shares, about US$0.0561 per Appili share, roughly a 117% premium.
Dec 14, 2023
Ceapro Inc.
Financial advisor to Ceapro · Healthcare / Biotech
Buyer Aeterna Zentaris Inc.
Aeterna Zentaris and Ceapro agreed to a merger of equals to create a diversified biopharmaceutical company.
Apr 28, 2022
Field Trip Health Ltd.
Financial advisor to Field Trip; fairness opinion to the board and special committee · Healthcare (Psychedelics)
Field Trip announced a plan of arrangement to separate its Discovery and Health divisions into two independent public companies.
Dec 2020
MindBeacon Holdings Inc.
Underwriter · Healthcare / Digital Health
MindBeacon completed its initial public offering, in which it and selling shareholders including TELUS sold 9.34 million common shares at $8.00 for gross proceeds of about $74.75 million.
Jun 16, 2016
Response Biomedical Corp.
Exclusive financial advisor to Response; fairness opinion and formal valuation to the special committee · Healthcare
Response Biomedical entered agreements for a going-private transaction and concurrent private placement, supported by a fairness opinion and formal valuation for the special committee.
Feb 23, 2012
YM BioSciences Inc.
Financial advisor to YM · Healthcare & Life Sciences
YM BioSciences completed an underwritten public offering of 40.25 million shares at US$2.00, including the over-allotment, for gross proceeds of US$80.5 million.
